In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI) of the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
(1) The total number of physicians to be contacted to obtain insurance information on all PLCO participants who had a positive cancer screening test;
(2) The percentage of physicians willing and able to provide insurance information;
(3) The percentage of respondents' patients with and without insurance, and possibly distribution of patients by insurance type;
(4) The number of participants for whom the insurance status can be only determined by self report;
(5) The percentage of PLCO participants who are willing to respond to the survey;
(6) The percentage of individuals who are willing to provide information on insurance status and type; and,
(7) The potential proportion of PLCO participants without health insurance at the time of screening.
The results of this feasibility study will be used to design of a larger study to examine the health care behavior of insured and uninsured PLPCO participants. This is relevant to understand the results of the PLCO Cancer Screening Trial and other screening trials currently being conducted in the U.S. The success of these trials is conditional on participants' access to care following a recommendation for follow-up. Uninsured individuals may be more likely to join these trials than insured ones in order to get free preventive care. They may also be more likely to not seek, or delay seeking, care after an abnormal screening test even though they are encouraged to get care and they may be highly motivated to receive the best care possible. It is relevant for other decision makers to understand whether uninsured persons are receiving appropriate care after abnormal screening results. The efforts to control cancer disease and the loss of life associated with it are concentrated on population wide screening. These endeavors may be compromised if a significant proportion of the population does not get appropriate follow-up after screening or does not get the care known to be effective for their disease.
The annualized cost to respondents is estimated at: $488. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.
To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Maria Pisu, Division of Preventive Medicine, University of Alabama at Birmingham, MT 628, 1530 3rd Avenue South, Birmingham, AL 35294–4410, or call non-toll-free number (205) 975–7366 or e-mail your request, including your address to: